Zentalis Pharmaceuticals (ZNTL) Total Current Liabilities (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Total Current Liabilities of $35.2 million for Q1 2026, down 28.72% year-over-year from $49.4 million in Q1 2025, and down 3.62% quarter-over-quarter from $36.6 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Total Current Liabilities (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $35.2 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 28.72% year-over-year to $35.2 million; the TTM figure through Mar 2026 stood at $35.2 million (down 28.72% YoY), while the FY2025 annual figure was $36.6 million, down 30.66% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $35.2 million, down from $36.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $69.4 million in Q4 2023, with the low at $35.2 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $52.7 million (2024), against an average of $50.9 million.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities jumped 44.85% in 2022, then tumbled 41.49% in 2025.
- Zentalis Pharmaceuticals' Total Current Liabilities stood at $56.6 million in 2022, then rose by 22.45% to $69.4 million in 2023, then declined by 23.99% to $52.7 million in 2024, then plunged by 30.66% to $36.6 million in 2025, then decreased by 3.62% to $35.2 million in 2026.
- Business Quant data shows ZNTL's Total Current Liabilities at $35.2 million in Q1 2026, $36.6 million in Q4 2025, and $37.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | 37.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.63 Mn |
| Mar 31, 2026 | 35.24 Mn |
| Dec 31, 2025 | 36.56 Mn |
| Sep 30, 2025 | 37.17 Mn |
| Jun 30, 2025 | 39.02 Mn |
| Mar 31, 2025 | 49.43 Mn |
| Dec 31, 2024 | 52.73 Mn |
| Sep 30, 2024 | 54.88 Mn |
| Jun 30, 2024 | 66.69 Mn |
| Mar 31, 2024 | 54.80 Mn |
| Dec 31, 2023 | 69.37 Mn |
| Sep 30, 2023 | 58.92 Mn |
| Jun 30, 2023 | 51.76 Mn |
| Mar 31, 2023 | 56.36 Mn |
| Dec 31, 2022 | 56.65 Mn |
| Sep 30, 2022 | 54.06 Mn |
| Jun 30, 2022 | 48.64 Mn |
| Mar 31, 2022 | 43.49 Mn |
| Dec 31, 2021 | 43.94 Mn |
| Sep 30, 2021 | 39.42 Mn |